A study evaluating SBP-101 in combination with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (PDA)
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2017
At a glance
- Drugs SBP 101 (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 21 Nov 2017 Planned initiation date changed to 1 Jan 2018.
- 14 Nov 2017 According to a Sun BioPharma media release, enrollment is expected to begin in first quarter of 2018.
- 05 Oct 2017 New trial record